GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Cipla Ltd

Cipla Q2 FY27 Results: PAT at INR 878 Cr, Total Income INR 7,404 Cr

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 27 Oct 2026, 01:36 PM IST  ·  BSE ID: b70d44a8-4116-490c-8c3a-07183918d0a5
View Original BSE Filing (PDF)
💡
In Simple Terms
Cipla's quarterly earnings showed lower profit and slightly lower total income, but its India sales grew significantly.
🤖 AI Summary
  • Cipla's Total Income from Operations for Q2 FY27 was INR 7,404 Cr, a -2% YoY decrease.
  • Net Profit After Tax (PAT) for Q2 FY27 stood at INR 878 Cr, decreasing -35% YoY.
  • One-India business achieved highest quarterly sales of INR 3,516 Cr, with 12% YoY growth.
  • North America segment delivered quarterly revenue of $ 172 Mn, improving sequentially by $10 Mn.
  • R&D investments amounted to INR 423 Cr, accounting for 5.7% of total sales in Q2 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Income from Operations
7,404 INR Cr
-2%
EBITDA
1,388 INR Cr
-26.7%
PAT
878 INR Cr
-35%
One-India Business Sales
3,516 INR Cr
12%
North America Revenue
172 Mn $
R&D Investments
423 INR Cr
Net Cash Position
9,823 INR Cr
🏢 How This Affects the Company
📈
Business Impact
The One-India business achieved its highest quarterly sales, driven by branded prescription, trade generics, and consumer health segments. North America saw sequential revenue improvement and strategic milestones like FDA approval for gAdvair Diskus and a new partnership for a Keytruda biosimilar.
💰
Financial Impact
Total Income from Operations decreased by -2% YoY, and PAT declined by -35% YoY. However, EBITDA margin expanded by 200 basis points QoQ to 18.7%. The company maintains a strong net cash position of INR 9,823 Cr.
⚙️
Operational Impact
Increased R&D investments of INR 423 Cr, or 5.7% of sales, are directed towards product filings and key development programs. The expansion of the trade generics portfolio with over 15 new launches indicates ongoing product development.
⚠️
Risk Impact
The Emerging Markets and Europe segment delivered $ 101 Mn in revenue despite geopolitical uncertainties and market-specific headwinds, indicating continued resilience in challenging environments.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the -35% YoY decline in PAT to INR 878 Cr and the -2% YoY decrease in total income to INR 7,404 Cr.
🔍
Management Signal
Management's statement emphasizes sustained business momentum, progress in focused markets, and continued focus on core business growth, productivity, and pipeline strengthening.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check for sustained India growth and North America pipeline contribution.
Updates on gAdvair Diskus commercialization and Keytruda biosimilar partnership progress.
Earnings conference call transcript — review leadership commentary on segment outlook.
MEDIUM RISK Significant YoY decline in PAT and overall revenue, despite strong performance in specific segments, indicates mixed financial health.
💡 Investor Takeaway
Cipla's Q2 FY27 Total Income from Operations was INR 7,404 Cr (-2% YoY) and PAT was INR 878 Cr (-35% YoY). The One-India business grew 12% YoY to INR 3,516 Cr, achieving its highest quarterly sales, while North America revenue increased sequentially to $ 172 Mn.
⚖️ Strengths & Concerns

✅ Positives

  • One-India business recorded highest quarterly sales at INR 3,516 Cr, achieving a solid 12% YoY growth.
  • North America segment's quarterly revenue improved sequentially by $10 Mn to $ 172 Mn.

⚠️ Concerns

  • Total Income from Operations decreased to INR 7,404 Cr in Q2 FY27, a -2% YoY decline from INR 7,589 Cr.
  • Profit After Tax (PAT) for Q2 FY27 decreased significantly to INR 878 Cr, down -35% YoY from INR 1,351 Cr.
📅 Company Track Record
Cipla's Q1 FY27 PAT declined 39.2% to INR 789 Cr, with Total Income growing 2% to INR 7,119 Cr. In Q4 FY26, PAT declined by -54.6% to INR 555 Cr, and FY26 PAT fell -26.5% to INR 3,879 Cr. This Q2 FY27 filing shows a sequential increase in PAT from Q1 FY27's INR 789.05 Crores to INR 877.54 Crore (per previous filing context).

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Cipla's net profit in Q2 FY27?
Cipla's Net Profit After Tax (PAT) for Q2 FY27 was INR 878 Cr, which represents a -35% YoY decrease from INR 1,351 Cr in Q2 FY26.
What was Cipla's total income from operations in Q2 FY27?
Cipla's Total Income from Operations for Q2 FY27 was INR 7,404 Cr, a -2% YoY decrease compared to INR 7,589 Cr in Q2 FY26.
How did Cipla's One-India business perform in Q2 FY27?
The One-India business recorded its highest quarterly sales of INR 3,516 Cr in Q2 FY27, achieving a solid 12% YoY growth.
What was Cipla's North America revenue for Q2 FY27?
Cipla's North America segment delivered quarterly revenue of $ 172 Mn in Q2 FY27, which is a $10 Mn improvement versus the previous quarter.
What were Cipla's R&D investments in Q2 FY27?
Cipla's R&D investments in Q2 FY27 stood at INR 423 Cr, accounting for 5.7% of its total sales for the quarter.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.